Riik: Singapur
keel: inglise
Allikas: HSA (Health Sciences Authority)
IPRATROPIUM BROMIDE
BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.
R03BB01
500 mcg/2 ml
SOLUTION
RESPIRATORY (INHALATION)
Prescription Only
BOEHRINGER INGELHEIM LTD
1994-05-13
0260-00 (SG) 20101223 ATROVENT ® ABCD COMPOSITION ATROVENT ® 250 mcg/2ml Solution for Inhalation in Unit Dose Vials 1 unit dose vial (1 or 2 ml) solution for inhalation contains 261 mcg (8r)-3 -hydroxy-8-isopropyl-1 H,5 H-tropanium bromide ( )-tropate monohydrate (= ipratropium bromide monohydrate) corresponding to 250 mcg ipratropium bromide anhydrous Excipients: sodium chloride, hydrochloric acid, purified water ATROVENT ® 500 mcg/2ml Solution for Inhalation in Unit Dose Vials 1 unit dose vial (1 or 2 ml) solution for inhalation contains 522 mcg (8r)-3 -hydroxy-8-isopropyl-1 H,5 H-tropanium bromide ( )-tropate monohydrate (= ipratropium bromide monohydrate) corresponding to 500 mcg ipratropium bromide anhydrous Excipients: sodium chloride, hydrochloric acid, purified water DESCRIPTION ATROVENT ® 250 mcg/2ml Solution for Inhalation in Unit Dose Vials Clear, colourless or almost colourless liquid, free from suspended particles ATROVENT ® 500 mcg/2ml Solution for Inhalation in Unit Dose Vials Clear, colourless or almost colourless liquid, free from suspended particles PROPERTIES Atrovent ® (ipratropium bromide) is a quaternary ammonium compound with anticholinergic (parasympatholytic) properties. In preclinical studies, it appears to inhibit vagally mediated reflexes by antagonizing the action of acetylcholine, the transmitter agent released from the vagus nerve. Anticholinergics prevent the increase in intracellular concentration of Ca++ which is caused by interaction of acetylcholine with the muscarinic receptor on bronchial smooth muscle. Ca++ release is mediated by th Lugege kogu dokumenti